OptiKira Company
OptiKira develops novel therapeutics intended to prevent cell death. It targets UPR and regulates its activity to prevent cell degeneration in idiopathic pulmonary fibrosis, nonalcoholic steatohepatitis, diabetes, cancer,, and various neurodegenerative diseases, enabling medical practitioners to treat Retinitis pigmentosa, amyotrophic lateral sclerosis, and other chronic diseases. OptiKira was founded in 2014 and is headquartered in Cleveland, Ohio.
Industry:
P4 Medicine
Headquarters:
Cleveland, Ohio, United States
Zip:
1-10
Founded Date:
2014-01-01
Employees Number:
1-10
Investors Number:
8250000
Total Funding:
Less than $1M
Estimated Revenue:
Less than $1M
Last Funding Date:
Grant
Last Funding Type:
ggaughan@optikira.com
Register and Claim Ownership